Jun 08, 2021 / 01:40PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Great. Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst. Very pleased to welcome AbbVie. Joining us today from the company, we have Michael Severino, Vice Chairman and President; Rob Michael, Executive Vice President and CFO; and Jeff Stewart, Executive Vice President, Commercial Operations. Thanks so much, gentlemen, for joining us today. Really appreciate the time.
Michael E. Severino - AbbVie Inc. - Vice Chairman & President
It's a pleasure to be here.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MDWell, maybe we'll jump right into it. Obviously, the COVID recovery is front and center for a number of folks. Maybe you could update us on the trends you're seeing across your various end markets, both in the U.S., Europe and Asia. And then how are you seeing those trends stack up in May versus what you saw back in April?
Michael E. Severino -
Trustpilot
